Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Proteomics ; 75(6): 1803-15, 2012 Mar 16.
Article in English | MEDLINE | ID: mdl-22245045

ABSTRACT

Head and neck squamous cell carcinoma (HNSCC) is usually found at a late stage and distant metastasis occurs at high frequency; therefore, novel prognostic markers are needed. This study was aimed to identify novel tumor markers in HNSCC. We identified 65 proteins which were significantly increased or decreased in the tumors by 2D-DIGE using 12 HNSCC and adjacent non-cancer tissues. Western blotting and immunohistochemical analysis confirmed that the expression of plectin was significantly increased in most cancer tissues as compared with non-cancer tissues. Strikingly, the suppression of endogenous plectin using siRNA inhibited the proliferation, migration and invasion of HNSCC cells and down-regulated Erk 1/2 kinase. Furthermore, immunohistochemistry using paraffin-embedded tissues from 62 patients showed not only that the frequency of recurrence was correlated with the plectin expression but that the prognosis of patients with a high plectin was extremely poor. Moreover, the survival rate of patients with a high plectin was significantly lower than that of patients with low E-cadherin levels, which is known to correlate with the poor prognosis of HNSCC. Our findings suggest that plectin promotes the migration and invasion of HNSCC cells through activation of Erk 1/2 kinase and is a potential prognostic biomarker of HNSCC.


Subject(s)
Carcinoma, Squamous Cell/diagnosis , Cell Movement/drug effects , Head and Neck Neoplasms/diagnosis , Plectin/physiology , Aged , Aged, 80 and over , Biomarkers, Tumor , Cell Line, Tumor , Female , Gene Knockdown Techniques , Humans , MAP Kinase Signaling System/drug effects , MAP Kinase Signaling System/physiology , Male , Middle Aged , Neoplasm Invasiveness/prevention & control , Plectin/genetics , Prognosis , RNA, Small Interfering , Squamous Cell Carcinoma of Head and Neck
2.
BMC Cell Biol ; 12: 41, 2011 Sep 27.
Article in English | MEDLINE | ID: mdl-21951621

ABSTRACT

BACKGROUND: We previously reported that periplakin (PPL) is downregulated in human esophageal cancer tissues compared to the adjacent non-cancer epithelium. Thus PPL could be a useful marker for detection of early esophageal cancer and evaluation of tumor progression, but largely remains unknown in this field. To investigate PPL involvement in carcinogenesis, tumor progression, cellular movement or attachment activity, siRNAs against PPL were transfected into pharyngeal squamous cancer cell lines and their effects on cellular behaviours were examined. RESULTS: PPL knockdown appeared to decrease tumor cell growth together with G2/M phase accumulation in cells attached to a culture dish. However, the extent of cell growth suppression, evaluated by the number of cells attached to the culture dish, was too distinctive to be explained only by cell cycle delay. Importantly, PPL knockdown suppressed cellular movement and attachment to the culture dish accompanied by decreased pAktSer473 phosphorylation. Additionally, LY294002, a PI3K inhibitor that dephosphorylates pAktSer473, significantly suppressed D562 cell migration. Thus PPL potentially engages in cellular movement al least partly via the PI3K/Akt axis. CONCLUSIONS: PPL knockdown is related to reduced cellular movement and attachment activity in association with PI3K/Akt axis suppression, rather than malignant progression in pharyngeal cancer cells.


Subject(s)
Carcinoma, Squamous Cell/metabolism , Cell Adhesion , Cell Movement , Pharyngeal Neoplasms/metabolism , Plakins/metabolism , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Cell Adhesion/genetics , Cell Cycle/genetics , Cell Growth Processes/genetics , Cell Line, Tumor , Cell Movement/drug effects , Cell Movement/genetics , Chromones/pharmacology , Humans , Morpholines/pharmacology , Pharyngeal Neoplasms/genetics , Pharyngeal Neoplasms/pathology , Phosphoinositide-3 Kinase Inhibitors , Phosphorylation/drug effects , Plakins/genetics , Proto-Oncogene Proteins c-akt/metabolism , RNA, Small Interfering/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...